PROT# MEL-041509: Phase II Randomized, Double-Blind, Placebo-Controlled, Three-Arm,Dose-Finding, Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis

Project: Research project

StatusFinished
Effective start/end date10/7/0910/7/12

Funding

  • OSI Pharmaceuticals, Inc. (MEL-041509)